Soleno Intangible Assets vs Deferred Long Term Liab Analysis
SLNO Stock | USD 52.71 3.13 5.61% |
Soleno Therapeutics financial indicator trend analysis is much more than just breaking down Soleno Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Soleno Therapeutics is a good investment. Please check the relationship between Soleno Therapeutics Intangible Assets and its Deferred Long Term Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
Intangible Assets vs Deferred Long Term Liab
Intangible Assets vs Deferred Long Term Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Soleno Therapeutics Intangible Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Soleno Therapeutics' Intangible Assets and Deferred Long Term Liab is -0.52. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Soleno Therapeutics, assuming nothing else is changed. The correlation between historical values of Soleno Therapeutics' Intangible Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Soleno Therapeutics are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Intangible Assets i.e., Soleno Therapeutics' Intangible Assets and Deferred Long Term Liab go up and down completely randomly.
Correlation Coefficient | -0.52 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most indicators from Soleno Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Soleno Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.As of the 2nd of December 2024, Selling General Administrative is likely to drop to about 7.4 M. In addition to that, Discontinued Operations is likely to drop to about (1.8 M)
Soleno Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Soleno Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Soleno Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 38.2M | 65.0M | 35.6M | 26.5M | 180.7M | 189.7M | |
Other Current Liab | 382K | 5.0M | 4.2M | 5.2M | 7.8M | 8.2M | |
Total Current Liabilities | 5.0M | 8.6M | 8.0M | 7.3M | 11.5M | 7.0M | |
Total Stockholder Equity | 14.9M | 45.5M | 17.8M | 10.3M | 157.5M | 165.4M | |
Other Liab | 18.1M | 10.8M | 9.6M | 8.8M | 10.2M | 9.1M | |
Property Plant And Equipment Net | 444K | 158K | 454K | 157K | 419K | 440.0K | |
Net Debt | (20.4M) | (49.1M) | (20.8M) | (14.4M) | (169.3M) | (160.8M) | |
Retained Earnings | (157.8M) | (182.4M) | (213.4M) | (237.4M) | (276.4M) | (262.6M) | |
Accounts Payable | 2.0M | 3.5M | 3.3M | 1.8M | 3.1M | 1.6M | |
Cash | 20.7M | 49.2M | 21.3M | 14.6M | 169.7M | 178.2M | |
Non Current Assets Total | 17.0M | 14.7M | 13.1M | 10.9M | 9.3M | 9.9M | |
Non Currrent Assets Other | 59K | 139K | 40K | 165K | 148.5K | 141.1K | |
Cash And Short Term Investments | 20.7M | 49.2M | 21.3M | 14.6M | 169.7M | 178.2M | |
Common Stock Total Equity | 19.2K | 32K | 45K | 80K | 92K | 96.6K | |
Common Stock Shares Outstanding | 2.3M | 4.2M | 5.3M | 8.4M | 16.5M | 17.3M | |
Liabilities And Stockholders Equity | 38.2M | 65.0M | 35.6M | 26.5M | 180.7M | 189.7M | |
Non Current Liabilities Total | 18.3M | 10.8M | 9.8M | 8.8M | 11.7M | 10.1M | |
Other Current Assets | 411K | 2.0M | 2.2M | 1.0M | 1.7M | 895.9K | |
Other Stockholder Equity | 172.7M | 227.9M | 231.1M | 247.8M | 433.9M | 455.6M | |
Total Liab | 23.2M | 19.4M | 17.8M | 16.1M | 23.2M | 15.1M | |
Property Plant And Equipment Gross | 444K | 158K | 522K | 157K | 508K | 533.4K | |
Total Current Assets | 21.1M | 50.2M | 22.4M | 15.6M | 171.4M | 179.9M | |
Common Stock | 19.2K | 32K | 45K | 80K | 8K | 30.7K | |
Property Plant Equipment | 22K | 19K | 454K | 157K | 180.6K | 110.1K | |
Net Tangible Assets | (1.6M) | 31.0M | 5.2M | (345K) | (396.8K) | (376.9K) | |
Retained Earnings Total Equity | (114.0M) | (127.0M) | (157.8M) | (182.4M) | (164.2M) | (172.4M) | |
Capital Surpluse | 140.5M | 157.4M | 172.7M | 227.9M | 262.1M | 149.3M | |
Deferred Long Term Liab | 5.4M | 5.2M | 12.2M | 539K | 485.1K | 460.8K | |
Intangible Assets | 16.5M | 14.6M | 12.6M | 10.7M | 8.7M | 11.4M | |
Non Current Liabilities Other | 6.1M | 10.3M | 9.5M | 8.8M | 11.5M | 7.0M | |
Net Invested Capital | 14.9M | 45.5M | 17.8M | 10.3M | 157.5M | 165.4M | |
Net Working Capital | 16.2M | 41.6M | 14.4M | 8.3M | 159.9M | 167.8M |
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Soleno Stock
0.65 | ME | 23Andme Holding Upward Rally | PairCorr |
0.64 | VALN | Valneva SE ADR | PairCorr |
0.45 | A | Agilent Technologies Sell-off Trend | PairCorr |
0.41 | DRMA | Dermata Therapeutics | PairCorr |
0.4 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.